About Us
History
We have a rich heritage spanning many decades, from our successful commercialisation of intellectual property to our transformation into a specialist healthcare company.
Along the way we have partnered with some of the world’s leading healthcare companies and played a part in the development of a number of significant medical innovations. Most recently, we have brought together three life sciences companies to create a growing specialist healthcare company that is focused on meeting the needs of specialist physicians and their patients.
| Date | Milestone |
|---|---|
| 2013 | Varisolve® (polidocanol endovenous microfoam (PEM)) new drug application (NDA) submitted to the US Food and Drug Administration (FDA); NDA accepted for full review |
| 2012 | Voraxaze® (glucarpidase) approved and launched in the US; Positive results reported from US pivotal Phase III trials of Varisolve® (polidocanol endovenous microfoam (PEM)); US and EU approve expanded Zytiga® (abiraterone acetate) indication for treatment of metastatic castration-resistant prostate cancer |
| 2011 | Acquisition of Biocompatibles International plc; Zytiga® approved in the US and EU |
| 2010 | BTG commences selling its own products in the US; Varisolve® (polidocanol endovenous microfoam (PEM)) commences Phase III trials in the US; DigiFab® (digoxin immune fab (ovine)) receives first European regulatory approval |
| 2009 | AstraZeneca initiates global Phase IIb study of AZD9773 (CytoFab™) |
| 2008 | Acquisition of Protherics PLC |
| 2006 | Divestment of the majority of the physical sciences IP portfolio |
| 2005 | Strategic business review leads to focus on life sciences |
| 2003 | Nobel Prize for Medicine awarded to inventor of MRI, a technology first licensed by BTG in the 1980s |
| 2002 | US launch of DigiFab®, a treatment for the toxic effects of over dosage with the heart drug digoxin |
| 2001 | US launch of CroFab® (crotalidae polyvalent immune fab (ovine)), the first new rattlesnake antivenom on the US market in 50 years; US approval of Campath® (alemtuzumab) and EU approval of MabCampath® (alemtuzumab) for chronic lymphocytic leukaemia |
| 1997 | BeneFIX® (coagulation factor IX (recombinant)) treatment for haemophilia B launched in the US |
| 1995 | BTG plc is listed on the London Stock Exchange (LSE:BGC (now LSE:BTG)) |
| 1992 | BTG is privatised |
| 1981 | BTG is formed from the merger of the National Research & Development Council and the National Enterprise Board |
| 1970s | Development and launch of: cholesterol assay tests; MRI; Oxford three-part knee |
| 1960s | Patenting/development of: continuously variable transmission; cephalosporin antibiotics; pyrethrin insecticides |
| 1950s | Patenting of interferon |
| 1948 | National Research Development Corporation founded by UK government to commercialise publicly funded research |
Maximising the potential of our assets
Our partnered programmes includes several products which we believe may have significant commercial potential.
BTG today
We've undergone significant change in recent years, streamlining the business to focus on what we do best.